

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2024

DIH HOLDING US, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-41250
(Commission File Number)

98-1624542
(IRS Employer
Identification No.)

77 Accord Park Drive;
Suite D-1
Norwell, Massachusetts
(Address of Principal Executive Offices)

02061
(Zip Code)

Registrant's Telephone Number, Including Area Code: 617 871-2101

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock	DHAI	The Nasdaq Stock Market LLC
Warrants	DHAIW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On August 19, 2024, DIH Holding US, Inc. (the “Registrant”) issued a press release announcing three months ended June 30, 2024 financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On August 19, 2024, the Registrant posted an updated investor deck to its website. A copy of the updated deck is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(a)-(b) Financial Statements.

(c) Exhibits.

99.1	Release dated August 19, 2024
99.2	Updated Investor Deck dated August 19, 2024
104	Cover Page Interactive Data File (Formatted in Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DIH HOLDING US, INC.

Date: August 19, 2024

By: /s/ Jason Chen

Jason Chen
Chief Executive Officer and Chairman

DIH Announces Fiscal 2025 First Quarter Financial Results

NORWELL, MA – August 19, 2024 DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced financial results for the quarter ended June 30, 2024, which is the first quarter of fiscal 2025.

Recent Highlights

- Revenue of \$16.2 million for the quarter ended June 30, 2024, representing growth of 24% over the prior year period
- Device revenue of \$12.3 million and service revenue of \$3.5 million for the quarter ended June 30, 2024, representing growth of 18% and 49%, respectively over the prior year period
- Revenue growth in both Europe, Middle East and Africa (EMEA) and the Americas of 54% over the prior year period
- Gross Margin of 53.5%, representing a 12 percentage point improvement over the prior year period
- Net loss of \$0.6 million, representing improvement of \$2.3 million over the prior year period
- DIH reiterates its expected full year 2025 revenue range of \$74 million to \$77 million, representing growth of approximately 15% to 20% over the full year 2024

"We are very pleased with the Company's performance in the first quarter of Fiscal Year 2025, showing significant progress over the same quarter last year," said Jason Chen, Chairman and CEO of DIH. "I am excited that two of our major strategic markets, EMEA and the Americas, each achieved growth of 54% and that recurring service revenue grew by 49%. Our team has increased account penetration and enhanced productivity through workflow efficiencies, as reflected in the significant improvements in both gross margin and net income. We will continue to enrich our product solution offerings throughout the year and I remain excited about the significant growth opportunities ahead of us."

Financial Results for the First Fiscal Quarter Ended June 30, 2024

Revenue for the three months ended June 30, 2024 increased by \$3.1 million, or 24.1%, to \$16.2 million from \$13.0 million for the three months ended June 30, 2023. The overall increase was primarily due to an increase in devices sold of \$1.8 million, or 17.6% year over year. The increase in devices revenue was primarily driven by higher sales volume in EMEA. Services revenue represented an increase of \$1.2 million, up 49.1% compared to the prior period. Other revenues were consistent compared to the prior period. Total revenue in EMEA and the Americas increased by \$3.6 million and \$1.6 million, respectively, to \$10.2 million and \$4.6 million for the three months ended June 30, 2024 compared to \$6.6 million and \$3.0 million for the three months ended June 30, 2023. The increase was partially offset by a decrease in sales in Asia.

The impact due to foreign currency translation resulted in a decrease of approximately \$0.1 million in revenue for the three months ended June 30, 2024.

Gross profit for the first fiscal quarter ended June 30, 2024, was \$8.7 million, an increase of 60.6% compared to the prior year period. The increase was driven by an increase of \$3.1 million in sales primarily in the EMEA region. Cost of sales was improved as compared to June 30, 2023, and was driven in part by a provision adjustment in the prior year that was not recurring in the current period.

Selling, general and administrative expense for the three months ended June 30, 2024 increased by \$2.8 million, or 48.2%, to \$8.7 million from \$5.8 million for the three months ended June 30, 2023. The increase was driven by a \$0.7 million increase in professional service costs related to audit, legal and other professional services along with an investment in finance capacity to support public company reporting obligations. Additionally, the increase included a \$0.7 million increase in performance-based compensation and a \$0.9 million increase in overhead expenses supporting the current growth. In addition, the Company implemented new guidance for the provision of credit losses during the three months ended June 30, 2023. The adjustment during the prior period reduced reserves on receivables in the prior year and, generated a benefit to the Company in the prior year that is not recurring as of the three months ended June 30, 2024.

Research and development costs for the three months ended June 30, 2024 increased by \$0.2 million, or 14.3%, to \$1.6 million from \$1.4 million for the three months ended June 30, 2023. The increase was primarily attributable to a \$0.2 million increase in personnel expenses related to increased employee compensation.

Cash and cash equivalents on June 30, 2024 totaled \$2.7 million.

Fiscal Year 2025 Outlook

The Company continues to expect gross revenue for fiscal year 2025 to range between \$74 million and \$77 million, representing approximately 15%-20% growth over fiscal year 2024.

About DIH Holding US, Inc.

DIH stands for the vision to “Deliver Inspiration & Health” to improve the daily lives of millions of people with disabilities and functional impairments through providing devices and solutions enabling intensive rehabilitation. DIH is a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Built through the mergers of global-leading niche technology providers, DIH is a transformative rehabilitation solutions provider and consolidator of a largely fragmented and manual-labor-driven industry.

Caution Regarding Forward-Looking Statements

This press release contains certain statements which are not historical facts, which are forward-looking statements within the meaning of the federal securities laws, for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements include certain statements made with respect to the business combination, the services offered by DIH and the markets in which it operates, and DIH’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions provided for illustrative purposes only, and projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These risks and uncertainties include, but are not limited to: general economic, political and business conditions; the ability of DIH to achieve its projected revenue, the failure of DIH realize the anticipated benefits of the recently-completed business combination and access to sources of additional debt or equity capital if needed. While DIH may elect to update these forward-looking statements at some point in the future, DIH specifically disclaims any obligation to do so.

Investor Contact

Greg Chodaczek
332-895-3230
Investor.relations@dih.com

DIH HOLDING US, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data, unaudited)

	<u>As of June 30, 2024</u>	<u>As of March 31, 2024</u>
Assets		
Current assets:		
Cash and cash equivalents	\$ 2,749	\$ 3,225
Accounts receivable, net of allowances of \$631 and \$667, respectively	5,690	5,197
Inventories, net	9,014	7,830
Due from related party	5,728	5,688
Other current assets	6,194	5,116
Total current assets	29,375	27,056
Property, and equipment, net	664	530
Capitalized software, net	2,052	2,131
Other intangible assets, net	380	380
Operating lease, right-of-use assets, net	4,388	4,466
Other tax assets	417	267
Other assets	933	905
Total assets	<u>\$ 38,209</u>	<u>\$ 35,735</u>
Liabilities and Deficit		
Current liabilities:		
Accounts payable	\$ 5,368	\$ 4,305
Employee compensation	3,991	2,664
Due to related party	9,790	10,192
Current portion of deferred revenue	6,350	5,211
Manufacturing warranty obligation	549	513
Current portion of long-term operating lease	1,509	1,572
Current maturities of convertible debt	1,461	—
Advance payments from customers	9,272	10,562
Accrued expenses and other current liabilities	9,950	9,935
Total current liabilities	48,240	44,954
Convertible debt, net of current maturities	1,177	—
Notes payable - related party	10,722	11,457
Non-current deferred revenues	4,747	4,670
Long-term operating lease	2,925	2,917
Deferred tax liabilities	89	112
Other non-current liabilities	4,304	4,171
Total liabilities	<u>\$ 72,204</u>	<u>\$ 68,281</u>
Commitments and contingencies		
Deficit:		
Preferred stock, \$0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and March 31, 2024	—	—
Common stock, \$0.0001 par value; 100,000,000 shares authorized; 34,544,935 shares issued and outstanding at June 30, 2024 and March 31, 2024	3	3
Additional paid-in-capital	3,685	2,613
Accumulated deficit	(35,826)	(35,212)
Accumulated other comprehensive income (loss)	(1,857)	50
Total deficit	<u>\$ (33,995)</u>	<u>\$ (32,546)</u>
Total liabilities and deficit	<u>\$ 38,209</u>	<u>\$ 35,735</u>

DIH HOLDING US, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data, unaudited)

	For the Three Months Ended June 30,	
	2024	2023
Revenue	\$ 16,187	\$ 13,045
Cost of sales	7,521	7,648
Gross profit	8,666	5,397
Operating expenses:		
Selling, general, and administrative expense	8,676	5,837
Research and development	1,644	1,438
Total operating expenses	10,320	7,275
Operating loss	(1,654)	(1,878)
Other income (expense):		
Interest income (expense)	(135)	(120)
Other income (expense), net	1,898	(689)
Total other income (expense)	1,763	(809)
Income (loss) before income taxes	109	(2,687)
Income tax expense	723	226
Net loss	\$ (614)	\$ (2,913)
Net loss per share, basic and diluted	\$ (0.02)	\$ (0.12)
Weighted average common shares outstanding, basic and diluted	34,545	25,000

DIH HOLDING US, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands, unaudited)

	For the Three Months Ended June 30,	
	2024	2023
Net loss	\$ (614)	\$ (2,913)
Other comprehensive (loss) income, net of tax		
Foreign currency translation adjustments, net of tax of \$0 and \$0	(1,388)	841
Pension liability adjustments, net of tax of \$0 and \$0	(291)	(420)
Other comprehensive (loss) income	(1,679)	421
Comprehensive loss	<u>\$ (2,293)</u>	<u>\$ (2,492)</u>

DIH HOLDING US, INC. AND SUBSIDIARIES
INTERIM CONDENSED COMBINED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)
(in thousands, unaudited)

	<u>Common Stock</u>		Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Equity (Deficit)
	Shares ⁽¹⁾	Amount				
Balance, March 31, 2023	25,000,000	\$ 2	\$ (1,898)	\$ (26,769)	\$ (289)	\$ (28,954)
Net loss	—	—	—	(2,913)	—	(2,913)
Other comprehensive loss, net of tax	—	—	—	—	421	421
Balance, June 30, 2023	25,000,000	\$ 2	\$ (1,898)	\$ (29,682)	\$ 132	\$ (31,446)
	Shares	Amount	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Equity (Deficit)
Balance, March 31, 2024	34,544,935	\$ 3	\$ 2,613	\$ (35,212)	\$ 50	\$ (32,546)
Net loss	—	—	—	(614)	—	(614)
Transaction relates to reverse recapitalization	—	—	710	—	—	710
Issuance of warrants	—	—	362	—	—	362
Other comprehensive income, net of tax	—	—	—	—	(1,907)	(1,907)
Balance, June 30, 2024	34,544,935	\$ 3	\$ 3,685	\$ (35,826)	\$ (1,857)	\$ (33,995)

DIH HOLDING US, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)

	For the Three Months Ended June 30,	
	2024	2023
Cash flows from operating activities:		
Net loss	\$ (614)	\$ (2,913)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	91	79
Provision for credit losses	(36)	(432)
Allowance for inventory obsolescence	(13)	693
Pension contributions	(150)	(150)
Pension expense	77	66
Foreign exchange (gain) loss	(1,899)	689
Noncash lease expense	422	375
Noncash interest expense	—	7
Deferred and other noncash income tax (income) expense	(166)	4
Changes in operating assets and liabilities:		
Accounts receivable	(489)	705
Inventories	(1,468)	(1,332)
Due from related parties	(108)	1,522
Due to related parties	(584)	(649)
Other assets	(872)	(398)
Operating lease liabilities	(425)	(518)
Accounts payable	1,508	36
Employee compensation	1,388	(160)
Other liabilities	—	189
Deferred revenue	1,411	209
Manufacturing warranty obligation	50	71
Advance payments from customers	(1,136)	2,229
Accrued expense and other current liabilities	1,003	(797)
Net cash used in operating activities	(2,010)	(475)
Cash flows from investing activities:		
Purchases of property and equipment	(235)	(15)
Net cash used in investing activities	(235)	(15)
Cash flows from financing activities:		
Proceeds from issuance of convertible debt, net of issuance costs	2,509	—
Payments on related party notes payable	(735)	(1,936)
Net cash provided by (used in) financing activities	1,774	(1,936)
Effect of currency translation on cash and cash equivalents	(5)	13
Net increase in cash, and cash equivalents, and restricted cash	(476)	(2,413)
Cash, and cash equivalents - beginning of period	3,225	3,175
Cash, and cash equivalents - end of period	\$ 2,749	\$ 762
Supplemental disclosure of cash flow information:		
Interest paid	\$ 135	\$ 113
Income tax paid	\$ —	\$ —
Supplemental disclosure of non-cash investing and financing activity:		
Accounts payable settled upon reverse recapitalization	\$ 710	\$ —

DIH

**DEDICATED TO RESTORING MOBILITY AND
ENHANCING HUMAN PERFORMANCE**

**Investor Presentation
August 2024**

Nasdaq: DHAI



In this presentation, "DIH", the "Company", "we", "us" and "our" mean DIH Holding US, Inc, a Delaware corporation (Nasdaq: DHA1). All amounts are in U.S. dollars unless otherwise indicated. The information contained herein does not purport to contain all of the information about the Company. The information contained herein has not been independently verified. No representations or warranties are made or implied with respect to the information contained herein.

This presentation contains forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, including without limitation the successful and timely completion and the commercialization of the products referred to herein. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks and strategies or deliverables stated herein, may involve, but are not limited to, comments with respect to the Company's business or financial objectives, its strategies or future actions, its targets, expectations for financial condition or outlook for operations. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and conditional, are intended to identify forward-looking statements.

Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. These assumptions are considered to be reasonable based on currently available information, but the reader is cautioned that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business. The forward-looking information set forth therein reflects expectations as of the date hereof and is subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Undue reliance should not be placed on forward-looking statements. The forward-looking statements contained in this presentation are expressly qualified by this cautionary statement.

This presentation is not intended to form the basis of any investment decision and there can be no assurance that any transaction will be undertaken or completed in whole or in part. The delivery of this presentation shall not be taken as any form of commitment on the part of the Company or its stockholders to proceed with any transaction, and no offers will subject the Company or its stockholders to any contractual obligations before definitive documentation has been executed. The Company reserves the right at any time without prior notice and without any liability to (i) negotiate with one or more prospective investors in accordance with any timetable and on any terms that the Company may decide, (ii) provide different information or access to information to different prospective investors, (iii) enter into definitive documentation and (iv) terminate the process, including any negotiations with any prospective investor without giving any reasons therefor.

DIH at a glance:

Robotic-enabled movement platform improving the lives of people with disabilities and functional impairments



Improving lives by providing human movement therapy while empowering leading scientists and clinics to study balance and movement disorders through **Advanced Technology**.





DIH – a Global Solution Provider, has **the broadest portfolio in neuro-rehabilitation and human performance research**, with over **4,500 devices installed**.

With an aging population and an increasing number of people living with neurological diseases, hospitals and clinics will be understaffed; **robotic rehabilitation fills the gap and helps therapists and patients thrive**.

More intensive, repetition-based therapy, supported by Advanced Technology **is shown to have superior patient outcomes** and can send them home sooner.

Technology solves the supply-demand problem in rehabilitation settings **by allowing occupational and physical therapists to work with multiple patients effectively**.

Bridges the gap between Clinical and Research applications **by enabling and inventing** the most advanced technological ways to study and treat balance and movement disorders.



1 HQ
 DIH Holding US



5 Commercial Regions
 USA, Singapore, Chile, Slovenia, Germany



3 Sites
 For R&D and manufacturing in CH, NL and USA



243 Employees
 in 9 global locations from 33 nationalities



19 Products & Systems



4,500+ Devices installed¹



1,500+ Medical device registrations
 in 75 countries



\$64.5M
 FY24² Revenue
 19% YoY increase



\$74M - \$77M
 FY25 Revenue Guidance
 17% YoY increase³



1,800
 Customer Accounts

¹ Includes clinical and research install base

² FY24 year ending March 31, 2024

³ FY25 YoY revenue growth at the midpoint of guidance

Meeting market demands with innovative Advanced Technologies

Health Providers

Research Facilities



Rehabilitation Hospitals



Physical Therapy and Rehab Clinics



Patients

Neurological



- Stroke
- SCI & cerebral palsy
- Parkinson's disease
- Traumatic brain injury

Orthopedic



- Amputation
- Osteoarthritis
- Musculoskeletal disorders

Geriatric & Pediatric




- Aging population with an increased risk of falling and functional impairment
- Pediatric patients with mobility impairments




**Research & Human
Movement Labs***
("Research Market")



**Rehabilitation
Hospitals and Outpatient Clinics**
("Hospital and Clinic Market")



ARM & HAND



GAIT & BALANCE



**DATA
INTEGRATION**

*Motek products are currently being sold by DIH through an exclusive relationship between Motek and DIH

¹ Two product lines available ² Product line consists of three products ³ Prototype available; In development

Aging population

>1B

Members of a growing elderly population, worldwide¹

46%+

of the world's aging population has disabilities²



Increasing neurological disorders and related disabilities

Est. **15%**

of the global population is affected by neurological disorders³

38%+

of stroke survivors were found to have disabilities⁴



Need of care and lack of therapist

Est. **2.4B**

People are currently living with a health condition that may benefit from rehabilitation⁵

1.09

physiotherapists per 1,000 people⁶




Advanced Technology is key to meeting market demands.

¹ WHO: Ageing and Health; <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>
² United Nations: Aging and Disability; <https://www.un.org/development/desa/disabilities/disability-and-ageing.html>
³ <https://pubmed.ncbi.nlm.nih.gov/36902495/>
⁴ NCBI: Causes and Trends of Disabilities in Community-Dwelling Stroke Survivors: A Population-Based Study; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833459/>

⁵ WHO: Rehabilitation; <https://www.who.int/news-room/fact-sheets/detail/rehabilitation#:~:text=Globally%2C%20an%20estimated%202.4%20billion,and%20characteristics%20of%20the%20population.>
⁶ 2020: World Physio; <https://world.physio/sites/default/files/2021-02/AMC2020-Europe.pdf> // WHO: <https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3408>; https://www.theglobaleconomy.com/rankings/physiotherapists_per_1000_people/



MMT: Manual Muscle Test for shoulder and/or elbow; MMT 2 for Armeo Senso =with arm weight support



FAC: Functional Ambulation categories


* Available only in the USA

INTENDED USE

TARGETS ALL ASPECTS OF BALANCE AND LOCOMOTION. THE USE OF VIRTUAL REALITY ENABLES RESEARCHERS TO ASSESS THE SUBJECT'S BEHAVIOR AND INCLUDES SENSORY INPUTS LIKE VISUAL, AUDITORY AND VESTIBULAR.

PROVIDES ANALYSIS AND THERAPY IN CHALLENGING CONDITIONS TO IMPROVE GAIT, WHILE REAL-TIME FEEDBACK ENABLES ANALYSIS AND TRAINING DURING THE SAME SESSION.


ENABLES MULTIPLE SYSTEM ENHANCEMENTS FOR ADDED FUNCTIONALITY OF GAIT-LAB.



CAREN EXTENDED*
Computer Assisted
Rehabilitation Environment



CAREN HIGH END*
Computer Assisted
Rehabilitation Environment



GRAIL*
Gait Real-time Analysis
Interactive Lab



M-GAIT*
Modular Gait Lab

*Motek products are currently being sold by DIH through an exclusive relationship between Motek and DIH

DIH provides a **broad portfolio of devices** and an **extensive range of services**,
to become a **Total Solution partner** for our customers



**BUSINESS MODEL
and PLANNING**

We provide guidelines and support customers in building their rehabilitation project. **We find the right solution to match the organizations' needs, space and budget.**



**CLINICAL
SERVICES**

To help make the best use of our solutions, we offer **clinical integration consulting and ongoing support**, as well as education and training.



**TECHNICAL
SERVICES**

We provide **technical support and regular maintenance** after installation so customers can maintain **clinical routines without disruption.**



**RESEARCH
SERVICES**

Research drives us forward and our **support and services** help institutions initiate their own research programs.



**MARKETING
SERVICES**

Customers **immediately stand out from other rehabilitation facilities.** With our support we make sure they are seen and heard.




>60

Leading Institutions trust DIH

DIH collaborates with world renowned institutions in rehabilitation and research as reference centers and innovation partners




**LOKOMAT
610**



**CAREN
204***



**ARMEO LINE
217**



**GRAIL &
M-Gait
234***



**ERIGO
60**



**C-Mill
70***

>1,300

Published Publications

>1,000 publications in peer-reviewed² journals
40+ ongoing studies

¹The Knowledge Platform includes all research articles, conference proceedings, and theses available on our devices and can be accessed via knowledge.hocoma.com and knowledge.motekmedical.com

²Reviewed and evaluated by a group of experts in the field before the article is published.

*Motek Products are currently being sold by DIH through an exclusive relationship between Motek and DIH



Early Entrants

Logos: LiteGait, motorika, bama technology, QJ REHAB, WALKBOT, XIANGYU MEDICAL



Emerging Players

Logos: BTE, EKS0 (NASDAQ), tyromotion, Bioness, THERA TRAINER, AXINE2IS, Aretech, BIONIK, LIFEWARD LFWD (NASDAQ), dorsaVi DVL (ASX), REHA TECHNOLOGY



Industry Leader

Logo: DIH DHAI (NASDAQ)

DIH is uniquely positioned as a leader in rehabilitation-tech and research markets



Leading Technology

Highly recognized premier brands and technologies in our industry, endorsed by leading rehabilitation institutes and opinion leaders



Product Portfolio

Broadest product portfolio in advanced robotics and sophisticated VR-enabled movement systems; most competitors operate in a single product category



Industry Experience

Organizational breadth and depth with significant experience in acquisition integration; key to our growth strategy and differentiation from competitors that are early in their organizational life cycles



Innovation

Sustained innovation capabilities with decades of proven expertise and resources



Tech Partnerships

Platform and core technology (hardware and software) supported by strong partnerships with leading research groups



Network Effect


Strong supporting functions and operational infrastructure that establish a platform network effect which will be difficult to replicate



Commercial Reach

Strong global market coverage with approx. 3-5x more sales volume than competitors


Global Market



- Global solution provider combining innovative robotic and VR technologies with clinical integration and proprietary insights.
- Transformative total solutions provider and consolidator in a fragmented and manual-labor-driven industry.
- Innovative and broad product portfolio, covering the entire continuum of care.
- Strong growth opportunity with \$64.5M revenue in FY24, representing 19% year-over-year growth.

¹ "Rehabilitation Robots Market by Product, End user and Geography – Forecast and Analysis (2023 – 2027)" November 2022

Way Forward - Investment Opportunity



¹ Grandview Research, October 14, 2022



Financial Highlights

Fiscal Year 2024

\$64.5M Revenue, +19% YoY growth

- 79% devices
- 17% services
- 4% other


(\$8.4M) Net Loss
46% Gross Margin
\$5.2M Cash Flow from Operations

First Quarter 2025

\$16.2M Revenue, +24% YoY growth

- 76% devices
- 22% services
- 2% other

\$(0.6M) Net Loss
54% Gross Margin
(\$2.0M) Cash Flow from Operations



Fiscal Year 2025 Revenue Guidance: \$74.0M-\$77.0M

*FY25 YoY revenue growth at midpoint of guidance



Jason Chen
Chief Executive Officer and
Chairman of the Board



Lynden Bass
Chief Financial Officer



Dr. Patrick Bruno
Chief Market Officer





CEO and Chairman of the Board
Jason Chen



Chief Financial Officer
Lynden Bass



**Chief Market Officer
Hospital & Clinic**
Patrick Bruno



**Vice President
Research**
Frans Steenbrink



**Senior Vice President
Sales – EMEA Indirect**
Slavko Skafar



**Vice President
Global Operations**
Walther Geiger



**Vice President
FP&A and Commercial Operations
Finance**
LaTonya Vincent

THANK YOU

For more information contact
investor.relations@dih.com

